US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.